Company intelligence / Profile preview

GlucoVista

Fairfield, New Jersey, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

GlucoVista is developing the CGM-305, a wearable non-invasive continuous glucose monitor using infrared spectroscopy to passively measure blood glucose. The device aims to replace finger-prick testing for diabetes management. As of the last reports, it was in clinical studies and had not yet received FDA clearance or commercial launch. No published results from pivotal trials or regulatory submissions were identified.

Therapeutic areas: Endocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

No major pharmaceutical or biotech partnerships reported; collaborating with hospitals in Israel for clinical studies

Beyond the preview

Go deeper on GlucoVista.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlucoVista.

Explore the full profile